... of Contents Nutrition, Exercise andProstateCancer Introduction Understanding the Links Between Nutrition, Exercise, andProstateCancer Effects of Oxidation and Inflammation The Contribution ... understanding of the roles of diet and exercise in the prevention of age-related diseases, as well as in the recurrence and progression of prostatecancer Nutrition, Exercise andProstateCancer ... Exercise andProstateCancer tissue that is removed surgically, and have found that inflammation leads to the atrophy, or wasting away, of normal prostate tissue adjacent to precancerous and cancerous...
... Protects ProstateCancer Cells from Apoptosis in Vitro and Confers Resistance to Androgen Depletion in Vivo Cancer Res 1995, 55:4438-4445 López-Otín C, Diamandis EP: Breast andProstate Cancer: ... upregulating telomerase activity in prostate epithelial cells and PC However, Table 2: Extended E-D model of breast cancerandprostatecancer Hormone receptor Property Membrane androgen receptor ↑apoptotic ... ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti -androgens BBRC 1990, 173:534-540 Mote PA, Leary JA, Avery KA, Sandelin...
... Murray T, Xu J, and Thun MJ Cancer statistics 2007 CA Cancer J Clin 2007; 57: 43-66 Li Y, and Cozzi PJ Targeting uPA/uPAR in prostatecancerCancer Treat Rev 2007;33(6):521-7 Catalona WJ and Smith ... step in the prostate tumorigenesis [59] C-myc is localized at chromosome [60] and its overrepresentation is associated with prostatecancer progression [61] Due to the fact that prostatecancer is ... permanent seed implants for localized prostatecancer BJU Int 2007; 99: 497-501 Sharifi N, Gulley JL, and Dahut WL Androgen deprivation therapy for prostatecancer JAMA 2005; 294: 238-244 Bloomfield...
... Prostate cancer: diagnosis and treatment ii Chapter Title Prostate cancer: diagnosis and treatment February 2008 iii Prostate cancer: diagnosis and treatment Published ... Intelligence unit and Surveillance (WCISU) Between 1996 and 2004 the age standardised incidence rate of prostatecancer increased in all cancer networks in England and Wales1 In England the average ... Source: cancer registries of England and Wales Data Source: Office of National Statistics and Ordnance Survey Prostate cancer: diagnosis and treatment 1.4 Survival In most cases prostate cancer...
... guideline .38 Introduction Prostatecancer is one of the most common cancers in men Every year there are 34,986 new cases in England and Wales and 10,000 deaths Prostatecancer is predominantly ... die with prostatecancerand those who might die from prostatecancer Why this is important The greatest uncertainties in managing prostatecancer are around the identification of which cancers ... professionals and men with prostatecancer is essential It should be supported by evidence-based written information tailored to the man's needs Treatment and care, and the information men with prostate cancer...
... with prostatecancerand 27,050 men will die from prostatecancer in the U.S Q How is prostatecancer diagnosed? A Prostatecancer is most often diagnosed by needle biopsy of the prostate gland ... urinary bladder in men Q How common is prostate cancer? A Prostatecancer is the most common form of cancer in men (except for skin cancer) and a leading cause of cancer death worldwide In 2007, close ... General Information about ProstateCancer Q What is prostate cancer? A Prostatecancer is an abnormal (malignant) growth of the prostate, a walnut-sized gland at the base of the urinary...
... expression in the androgen responsive prostatecancer cell line LNCaP It is an oncogene overexpressed in prostate, breast and ovarian cancer, as demonstrated by DNA microarray analysis and high density ... et al (2004) PrLZ, a novel prostate- specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostatecancerCancer Res 64, 1589–1594 Byrne ... transcriptional and translational levels is positively regulated by estradiol in breast cancer cells [5] andandrogens in prostatecancer cells [9,10,14,27] From the present study, we noted that dysregulation...
... behaviour, STDs and risks for prostatecancer Br J Cancer 82, 718–725 57 Andersson, S O., Baron, J., Bergstrom, R., Lindgren, C., Wolk, A., and Adami, H O (1996) Lifestyle factors andprostatecancer ... the prostate of prostatecancer cell lines or by growing Human ProstateCancer 23 Table Profile of Established Human ProstateCancerand Immortalized Cell Lines Cell line PC-93 PC-3 AD primary prostate ... protein, and dehydroepiandrosterone: Risk of prostatecancer in black and white men Cancer Epidemiol Biomarkers Prev 4, 655–659 36 Nickerson, T and Huynh, H (1999) Vitamin D analogue EB1089-induced prostate...
... all three prostatecancer cell lines (LNCaP, DU145 and PC-3) and in surgically resected prostatecancer tissues (Figure 1B and 1C) Low levels of expression were detected in non-cancerous prostate ... prostatecancer (Table and Figures 4, 5, and 7) CTLs could not be induced in any of the patients with AMACR-negative prostatecancer In five cases (cases 1, 2, 3, and 6) with AMACR-positive prostate ... detected in three prostatecancer cell lines (LNCaP, DU145 and PC-3) C Expression of AMACR in cancer tissues and noncancerous tissues from surgical specimens of two prostatecancer cases other...
... items, which assess patient function (FACT-G) and a 12-item prostatecancer subscale (PCS) to assess symptoms and problems specific to prostatecancer In addition, the 26-item Trial Outcome Index ... Campbell ML: Expression of the protooncogene bcl-2 in the prostateand its association with emergence of androgen-independent prostatecancerCancer Res 1992, 52:6940-6944 Banerjee PP, Banerjee S, ... I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostatecancerand other advanced malignancies Cancer Chemother Pharmacol 2003, 52:119-124 Bray K, Chen...
... advanced-stage prostate cancer: the ProstateCancer Outcomes Study J Natl Cancer Inst 2001, 93:388-395 Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray T, Henley J, Liff J, Thun MJ: Cancer ... of these regions (5p15.33 and 16p11.2) have been previously reported as common areas of genomic gain in prostatecancer In one series of 18 prostatecancer cell lines and xenografts, 39% of samples ... sipuleucel-T in advanced prostatecancerCancer 2009, 115:3670-3679 29 Saramaki OR, Porkka KP, Vessella RL, Visakorpi T: Genetic aberrations in prostatecancer by microarray analysis Int J Cancer 2006, 119:1322-1329...
... Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the ProstateCancer ... correlation between SF and SB is maintained for years, after which function and bother appear to have divergent trajectories Background Methods Prostatecancerand its treatments are costly and significantly ... advanced prostatecancer Urology 2007, 69:1170-5 Ward JF, Slezak JM, Blute M, Bergstralh EJ, Zincke H: Radical prostatectomy for clinically advancer (cT3) prostatecancer since the advent of prostate- specific...
... tumor Background Prostatecancer is the most frequently diagnosed cancerand the second leading cause of cancer- related deaths for males in the USA One promising approach in prostatecancer diagnosis ... pressure and the regulation of cell growth in some malignant cell lines [1, 2] The presence of GRPR has been documented in small cell lung cancers [3], prostate cancers [4, 5], breast cancers [6-8] and ... two BBN(6-14) ligands and the chelator In vitro GRPR-binding affinities were determined with competitive binding assays on PC3 human prostatecancer cells In vivo stability and biodistribution...
... compare cancer incidence of the Saarland Aussiedler cohort to the Saarland population The Saarland Cancer Registry provided data on Saarland population figures and number of cancer cases (Saarland Cancer ... with regard to all cause mortality, and overall cancerandprostatecancer incidence and mortality For prostatecancer we also consider the influence of age and length of stay in Germany in order ... lowest prostatecancer rates with regard to mortality and incidence are seen in Hong Kong Scandinavian countries are among those with the highest prostatecancer mortality worldwide Prostate cancer...
... grade 2.2 CNTs preparation MWCNTs were purified and oxidized in a 1:1 mixture of HNO3 and H2SO4 at 90 1C for h, then washed with distilled water until pH and separated by centrifugation The solid residue ... PGSTAT30 for frequencies between 100 kHz and 100 mHz and a perturbation amplitude of 10 mV Solutions were systematically deaerated with argon before and during experiments Field Emission Scanning ... distilled water and immersed into 500 μL of an aqueous solution containing 0.1 μM ODN probe for h at 37 1C Electrodes were then washed with MilliQ water and PBS at room temperature and immersed...
... including prostatecancerand overcoming resistance to standard genotoxic chemo- and radiotherapy Importantly, Akt is embedded into a highly complex network of upstream regulators and downstream ... Cell lines and cell culture The prostatecancer cell lines LNCaP (p53 wild type, androgen-dependent, highly differentiated), PC3 (p53-/-, androgen-independent, poorly differentiated), and DU145 ... Page of 12 Figure Anti-neoplastic effects of ErPC3 and ionizing radiation on prostatecancer cells The prostatecancer cell lines PC3, DU145, and LNCaP, were irradiated (RT) with 2, 5, or 10 Gy...
... alkylphospholipid perifosine in CWR22RV1 prostatecancer both in vitro and in vivo In vitro, perifosine reduced cell viability and clonogenic survival, and enhanced apoptosis after radiation In ... perifosine and fractions of Gy radiation daily Variation between our results and previous results are likely caused by the differences in radiosensitivity between squamous cell carcinoma andprostatecancer ... perifosine in prostatecancer PC-3 cells Cells were irradiated in the absence (control) or in the presence of perifosine and the colony formation assay was conducted Shown are the means and standard...
... line) and primary prostatecancer (n = 7; dashed line) The and year DDFS rates are 100% and 75% for primary, and 90% and 75% for recurrent tumours The difference between primary and recurrent cancers ... for primary and recurrent prostatecancer The maximum standardized uptake value (SUVmax) is given for primary and recurrent prostatecancer receiving a Choline-PET/CT for diagnosis and radiotherapy ... for recurrent (n = 17; dashed line) and primary prostatecancer (n = 7; blue solid line) The and year BRFS rates are 83.3% and 83.3% for primary, and 82.5% and 48.9% for recurrent tumours The...